Evangeline Armstrong-Gordon1, Danijela Gnjidic2,3, Andrew J McLachlan1,4, Bayan Hosseini5, Andrew Grant5, Philip J Beale6, Nial J Wheate7. 1. Sydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia. 2. Sydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au. 3. Charles Perkins Centre, The University of Sydney, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au. 4. Centre for Education and Research in Ageing, Concord Repatriation General Hospital, Sydney, NSW, 2139, Australia. 5. Oncology Pharmacy Department, Concord Repatriation General Hospital, Sydney Local Health District, Sydney, NSW, 2139, Australia. 6. Concord Cancer Centre, Concord Repatriation General Hospital and Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia. 7. Sydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia. nial.wheate@sydney.edu.au.
Abstract
PURPOSE: Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions. METHODS: A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015. RESULTS: Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia. CONCLUSIONS: The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.
PURPOSE:Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions. METHODS: A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015. RESULTS: Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia. CONCLUSIONS: The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancerpatients and most patients receive a dose reduction during treatment.
Authors: Corey J Langer; Jennifer Moughan; Benjamin Movsas; Ritsuko Komaki; David Ettinger; Jean Owen; J Frank Wilson Journal: Lung Cancer Date: 2005-04 Impact factor: 5.705
Authors: Lynda M McEvoy; Sharon A O'Toole; Cathy D Spillane; Cara M Martin; Michael F Gallagher; Britta Stordal; Gordon Blackshields; Orla Sheils; John J O'Leary Journal: BMC Cancer Date: 2015-07-25 Impact factor: 4.430
Authors: Đenana Miodragović; Antonello Merlino; Elden P Swindell; Abraham Bogachkov; Richard W Ahn; Sara Abuhadba; Giarita Ferraro; Tiziano Marzo; Andrew P Mazar; Luigi Messori; Thomas V O'Halloran Journal: J Am Chem Soc Date: 2019-04-15 Impact factor: 16.383